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In Vivo Degradation of Heparan Sulfates in the Glomerular
Basement Membrane Does Not Result in Proteinuria
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Leo A.H. Monnens,† Ron A. Wevers,‡ Angelique L.W.M.M. Rops,§ Johan van der Vlag,§
Jo H.M. Berden,§ Lambert P.W.J. van den Heuvel,† and Toin H. van Kuppevelt*
*Department of Matrix Biochemistry and §Nephrology Research Laboratory, Nijmegen Centre for Molecular Life
Sciences, and †Department of Pediatric Nephrology and ‡Laboratory of Pediatrics and Neurology, Radboud University
Nijmegen Medical Centre, Nijmegen, The Netherlands
Heparan sulfates (HS) are long, unbranched, negatively charged polysaccharides that are bound to core proteins. HS in the
glomerular basement membrane (GBM) is reported to be important for charge-selective permeability. Aberrant GBM HS
expression has been observed in several glomerular diseases, such as diabetic nephropathy and membranous glomerulopathy,
and a decrease in HS generally is associated with proteinuria. This study, with the use of a controlled in vivo approach,
evaluated whether degradation of HS in rat GBM resulted in acute proteinuria. Rats received two intravenous injections of
either heparinase III to digest HS or neuraminidase to remove neuraminic acids (positive control). Urine samples were taken
at various time points, and at the end of the experiment, kidneys were removed and analyzed. Injection with heparinase III
resulted in a complete loss of glomerular HS as demonstrated by immunofluorescence staining using anti-HS antibodies and
by electron microscopy using cupromeronic blue in a critical electrolyte concentration mode. In the urine, a strong increase in
HS was found within 2 h after the first injection. Staining for agrin, the major HS proteoglycan core protein in the GBM, was
unaltered. No urinary albumin or other proteins were detected at any time point, and no changes in glomerular morphology
were noticed. Injection of rats with neuraminidase, however, resulted in a major increase of urinary albumin and was
associated with an increase in urinary free neuraminic acid. An increased glomerular staining with Peanut agglutinin lectin,
indicative of removal of neuraminic acid, was noted. In conclusion, removal of HS from the GBM does not result in acute
albuminuria, whereas removal of neuraminic acid does.
J Am Soc Nephrol 18: 823–832, 2007. doi: 10.1681/ASN.2006070692
I n normal physiology, low molecular weight proteins anda fraction of high molecular weight proteins cross theglomerular filtration barrier and generally are reabsorbed
and catabolized by the proximal tubular epithelial cells. Dys-
function of the glomerular capillary wall results in proteinuria,
and proteins of the size of albumin (69 kD, approximately 36 Å)
or larger then appear in the urine (1,2).
The glomerular capillary wall is composed of three layers: (1)
The endothelial cells with their fenestrae (50 to 100 nm in
diameter), (2) the glomerular basement membrane (GBM; 300
to 350 nm in thickness), and (3) the visceral epithelial cells
(podocytes) with their foot processes interconnected by slit
diaphragms (3). The GBM contains large amounts of heparan
sulfate proteoglycans (HSPG) that are composed of a core pro-
tein and heparan sulfate (HS) side chains, which are long,
unbranched, strongly anionic polysaccharides that belong to
the family of glycosaminoglycans (GAG). The major HSPG
found in the GBM is agrin (4,5). The HS chains are composed of
alternating glucosamine and d-glucuronic/l-iduronic acid res-
idues, which are negatively charged as a result of the presence
of multiple carboxylic groups and N-, 2-O-, 6-O-, and 3-O-
sulfate groups (6,7). Therefore, HS in the GBM is assumed to
repel negatively charged proteins, including albumin, and pre-
vent their filtration (charge-selective barrier). The glomerular
endothelial cell surface layer, the glycocalyx, is also thought to
contribute to the charge-selective barrier in the glomerular filter
(3,8,9) and contains in addition to HSPG negatively charged sialic
acids that are constituents of glycoproteins and glycolipids of the
cell membrane (8). The most frequent sialic acid is N-acetylneura-
minic acid (10). Finally, the slit diaphragms, which interconnect
the podocyte foot processes, also play an important role in the
filtration characteristics of the glomerulus (1).
Alterations in glomerular HS expression have been reported
in a number of renal pathologies, including diabetic nephrop-
athy (11–14), minimal-change disease (14,15), and membranous
glomerulopathy (14). A decreased GBM HS expression gener-
ally correlates with an increase in the level of proteinuria
(13,16), but it is still not clear whether a decrease in glomerular
HS is a cause or a consequence of proteinuria.
Two observations have fueled the idea that HS is involved
directly in the charge-selective characteristics of the GBM. First,
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intravenous injection of rats with the monoclonal anti-HS an-
tibody JM403 resulted in a dosage-dependent increase in albu-
minuria (17). Second, in isolated rat kidneys or glomeruli that
were perfused with the HS-degrading enzyme heparinase III or
with charge-neutralizing protamine, native ferritin molecules
(18,19) and BSA (19,20) were found to penetrate the GBM and
reach the urinary space. However, in a study by Jeansson et al.
(21), the role of HS on glomerular filtration was not obvious. It
should be noted that in none of these studies thoroughly eval-
uated the removal or blocking of HS. Because it still is not clear
whether HS plays a major role in the development of protein-
uria, the aim of our study was to investigate in a controlled in
vivo study the functional importance of this polysaccharide for
glomerular permeability of proteins.
Materials and Methods
Experimental Setup
Before injection into the tail vein of rats, the enzymatic activities of
heparinase III (E.C. 4.2.2.8; from Flavobacterium heparinum; molecular
weight 73 kD; IBEX, MT-Royal, QU, Canada) and 2-3,6,8-neuramini-
dase (E.C. 3.2.1.18; from Vibrio cholerae; molecular weight 90 kD; Cal-
biochem, La Jolla, CA) were evaluated in situ. Rat cryosections (2 m)
were preincubated with heparinase III in 25 mM Tris (pH 8.0) or
neuraminidase in 50 mM sodium acetate and 1 mM CaCl2 for 2 h at
37°C. HS staining (see the Immunofluorescence Staining section) was
abolished after pretreatment of cryosections with 0.02 IU/ml hepari-
nase III, whereas complete removal of neuraminic acid was found using
0.04 IU/ml neuraminidase (Figure 1). On the basis of these results and
taking into account that Wistar rats contain approximately 10 ml of
plasma, 0.2 to 0.4 IU of heparinase III and 0.4 IU neuraminidase were
administered intravenously. Using a protease fluorescence detection kit
(Sigma, St. Louis, MO) according to the manufacturer’s protocol, we
checked whether the heparinase III and neuraminidase solutions con-
tained protease activity. No protease activity was detected in the en-
zyme solutions.
Male Wistar rats (250 to 300 g) were housed in the animal facilities of
the Central Animal Facility of the Radboud University Nijmegen Med-
ical Centre with free access to standard pelleted food and drinking
water. The animal ethics board approved all animal experiments. Rats
received two intravenous injections of 1 ml of PBS that contained the
enzymes heparinase III or neuraminidase. The experiment was per-
formed according to the schedule shown in Table 1. Briefly, rats were
administered two injections (t  0 h and t  24 h) of heparinase III (0.2
IU) or PBS via the tail vein and killed 48 h after the first injection.
Another set of rats were administered an injection of 0.4 IU instead of
0.2 IU of heparinase III and with a shorter interval between the injec-
tions (8 instead of 24 h). In addition, rats were administered an injection
of neuraminidase (0.4 IU), which served as a positive control for the
evaluation of our in vivo system, because this treatment resulted in
proteinuria (22). The rats were killed 24 h after the first injection. Two
rats were taken per experimental condition. For obtaining urine sam-
ples, rats were placed individually into metabolic cages immediately
after the first injection. At the end of the experiment, blood was col-
lected to obtain serum. Kidneys were removed and processed for
immunofluorescence staining, general histology, and electron micros-
copy.
Immunofluorescence Staining
Frozen rat kidneys were sliced into 2-m sections and stored at
20°C until use. After air-drying, cryosections were blocked with PBS
that contained 2% (wt/vol) BSA and 0.05% (vol/vol) Tween-20 (block-
ing buffer) for 20 min. Cryosections then were incubated with phage
display–derived anti-HS antibodies (produced in our laboratory [23–
25] and recognizing sulfated HS domains) in blocking buffer for 1 h. As
a negative control, an antibody from an irrelevant clone (MPB49) was
used. This antibody, which is 95% identical to the antibodies used,
does not stain kidney tissue sections. Bound antibodies were detected
by incubation with mouse anti-VSV tag IgG antibody P5D4 (1:10;
Boehringer Mannheim, Mannheim, Germany), followed by Alexa 488–
conjugated goat anti-mouse IgG (1:200; Molecular Probes, Eugene, OR),
both for 45 min. Also, anti-HS antibody JM403 (26) (1:400) was used,
which was visualized using Alexa 488–conjugated goat anti-mouse
IgM (1:200; Molecular Probes). After each antibody incubation, cryo-
sections were washed three times for 5 min with PBS that contained
0.1% (vol/vol) Tween-20. Finally, cryosections were fixed in 100%
(vol/vol) ethanol for approximately 10 s, air-dried, and embedded in
10% (wt/vol) mowiol (Calbiochem). Reactivity of heparinase III was
evaluated further by incubation of cryosections with anti-HS stub an-
tibody 3G10 (1:100; Seikagaku, Tokyo, Japan), which was visualized
using Alexa 488–conjugated goat anti-mouse IgG.
To study the effect of neuraminidase, we used Sambucus nigra lectin
(1:1000; Vector Laboratories, Burlingame, CA), which preferentially
binds 2,6-linked neuraminic acid (Neu5Ac2–6Gal), and Peanut ag-
glutinin lectin (1:1000; Vector Laboratories), which binds to an epitope
that becomes available after removal of neuraminic acid (Gal1–3Gal-
NAc). Cryosections first were blocked with streptavidin (1:1000;
Sigma), followed by d-biotin (1:1000; Sigma), both for 15 min. This was
followed by incubation with biotin-labeled lectin for 1 h and Alexa
488–conjugated streptavidin (1:200; Molecular Probes) for 45 min.
Figure 1. Evaluation of the activity of heparinase III and neuraminidase in situ. Renal heparan sulfate (HS) and neuraminic acid
expression were demonstrated by immunofluorescence staining of rat cryosections before and after enzyme treatment. Staining
for HS (antibody HS4C3) was completely abolished by pretreatment of kidney sections with 0.02 IU heparinase III/ml (A).
Neuraminic acid staining with Sambucus nigra (SNA) lectin was abolished after preincubation with 0.04 IU neuraminidase/ml (B).
Bar  50 m; magnification is identical for each photograph.
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Staining for the HSPG core protein agrin was performed using anti-
body MI91 (5) (1:800), which was visualized using CY3-conjugated goat
anti-hamster IgG (1:800; Jackson ImmunoResearch, Suffolk, UK). Ex-
pression of the podocyte-associated, neuraminic acid–containing pro-
tein podocalyxin was studied using antibody ASD-86 (culture super-
natant 1:20; provided by the Department of Pathology, Radboud
University Medical Centre Nijmegen, Nijmegen, The Netherlands),
which was visualized using Alexa 488–conjugated goat anti-mouse
IgG. Staining of the sections was examined using a Leica CTR6000
microscope (Leica Microsystems GmbH, Wetzlar, Germany).
General Histology
Paraffin-embedded kidneys of the injected rats were sliced into 5-m
sections. After deparaffinization, sections were incubated with
Delafield’s hematoxylin (Merck, Darmstadt, Germany) for 20 min, fol-
lowed by incubation with 0.3% (wt/vol) eosin (Merck) in 96% ethanol
for 30 s. After dehydration in 100% (vol/vol) ethanol and xylene,
sections were embedded in entallan (Merck). Staining of the sections
was examined using a Leica CTR6000 microscope.
Electron Microscopy
To visualize GAG, we applied the critical electrolyte concentration
method as described previously (27). Kidney tissue was fixed overnight
in 25 mM sodium acetate (pH 5.6) that contained 2.5% (vol/vol) glu-
taraldehyde, 0.2 M MgCl2, and 0.2% (wt/vol) cupromeronic blue
(Seikagaku, Tokyo, Japan). Tissue was washed three times for 10 min
with the same solution without cupromeronic blue and three times for
10 min with distilled water that contained 1% (wt/vol) Na-tungstate.
Tissue was dehydrated in ascending concentrations of ethanol, the 30
and 50% concentrations containing 1% Na-tungstate, followed by two
incubations with 100% (vol/vol) ethanol, both for 1 h. Subsequently,
tissue was incubated two times for 20 min with 100% (vol/vol) pro-
pylene oxide, followed by incubation with 50% (vol/vol) propyleneox-
ide and 50% (vol/vol) Epon overnight and with 100% (vol/vol) Epon
for another night. Finally, tissue was embedded by increasing the
temperature (37, 45, and 60°C for 24 h each). Ultrathin sections were
prepared and studied using a JEOL TEM 1010 microscope (JEOL Ltd.,
Tokyo, Japan).
For studying the renal ultrastructure, kidney tissue was fixed in 2.5%
(vol/vol) glutaraldehyde in 0.1 M phosphate buffer (pH 7.3) overnight
at 4°C. Tissue was washed three times for 20 min with 0.1 M phosphate
buffer and postfixed in 1% (wt/vol) osmium tetroxide (Electron Mi-
croscopy Sciences, Washington, PA) in 0.1 M phosphate buffer for 1 h.
After washing three times for 20 min with 0.1 M phosphate buffer,
tissue was dehydrated in ascending concentrations of ethanol, followed
by two incubations with 100% (vol/vol) ethanol, both for 1 h. Further
embedding in Epon was performed as described previously. Ultrathin
sections, which were poststained with lead citrate and uranyl acetate,
were prepared and then examined using a JEOL TEM 1010 microscope.
Urine and Serum Analyses
In all animals, urinary creatinine, GAG, neuraminic acid, protein, and
N-acetyl--d-glucosaminidase activity were determined in timed urine
collections. Serum creatinine was determined in blood that was ob-
tained at the time of killing.
Creatinine. Urinary and serum creatinine were measured enzy-
matically as described by Suzuki and Yoshida (28), using the Aeroset
apparatus from Abbott (Hoofddorp, The Netherlands). All reagents
were obtained from Roche Diagnostics (Almere, The Netherlands).
Creatinine clearance (ml/min) was calculated by the following for-
mula: [(urinary creatinine (mol/ml)/serum creatinine (mol/ml)] 
[urinary volume (ml)/time (min)].
Glycosaminoglycans. Urinary GAG were determined by agarose
gel electrophoresis, which separates GAG on basis of backbone struc-
ture. Staining was by combined azure A–silver treatment as described
by van de Lest et al. (29).
Neuraminic Acid. Urinary neuraminic acid was measured enzy-
matically using a colorimetric assay (Roche, Almere, The Netherlands)
according to the manufacturer’s protocol and was expressed as the ratio
between urinary neuraminic acid and urinary creatinine (mol neura-
minic acid/mmol creatinine).
Proteins. A qualitative examination of proteins in the urine of the
injected rats was carried out by SDS-PAGE followed by Coomassie
brilliant blue staining as described by Laemmli et al. (30). As a control,
a urine sample of a rat with tubular dysfunction (provided by Suzanne
Heemskerk, Department of Pharmacology and Toxicology, Nijmegen
Centre for Molecular Life Sciences, Nijmegen, The Netherlands) was
included. This rat was administered an intraperitoneal injection of 5
mg/kg body wt of the endotoxin LPS and killed after 48 h.
Urinary albumin was analyzed quantitatively using an ELISA kit
(Bethyl Laboratories, Montgomery, TX) according to the manufactur-
er’s protocol. Urinary albumin was expressed as the ratio between
urinary albumin and urinary creatinine (mg albumin/mg creatinine).
N-acetyl--D-Glucosaminidase Activity. Urinary activity of
N-acetyl--d-glucosaminidase, which is a marker for proximal tubular
dysfunction, was determined using the MultiPROBE II apparatus.
Urine was incubated with 12.5 mM 4-methylumbelliferyl-N-acetyl--
d-glucosaminide (Sigma) in 0.1 M citric acid (pH 4.4) for 10 min at 37°C.
The enzymatic reaction was stopped by the addition of 0.5 M glycine
buffer (pH 10.6) that contained 0.025% (vol/vol) Triton, and fluores-
cence was measured. Urinary N-acetyl--d-glucosaminidase activity
was expressed as the ratio between urinary N-acetyl--d-glucosamin-
ide and urinary creatinine (nmol N-acetyl--d-glucosaminide/h per
mol creatinine).
Table 1. Experimental setupa
Enzyme Solution Time of Injection Time of Killing
0.2 IU heparinase III in PBS t  0 h and t  24 h t  48 h
PBS t  0 h and t  24 h t  48 h
0.4 IU heparinase III in PBS t  0 h and t  8 h t  24 h
0.4 IU neuraminidase in PBS t  0 h and t  8 h t  24 h
PBS t  0 h and t  8 h t  24 h
aIU definition: Amount of enzyme that will produce 1 mol of product per minute under specified conditions of buffer,
pH, and temperature.
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Results
Glomerular HS and Neuraminic Acid Are Removed after
Heparinase III and Neuraminidase Injection, Respectively
Immunofluorescence Studies. To evaluate whether hepa-
rinase III had removed HS in vivo, we investigated the presence
of HS in the kidney by immunofluorescence staining. Injection
of heparinase III into rats resulted in disappearance of staining
of renal tissue as demonstrated with the phage display–derived
anti-HS antibodies HS4C3 and EW3D10 (Figure 2, A and B),
which both recognize sulfated HS domains. In addition, ab-
sence of staining was observed with anti-HS antibody JM403
(Figure 2C), which defines a poorly/nonsulfated HS epitope
that contains N-unsubstituted glucosamine and d-glucuronic
acid residues (26). With anti-HS stub antibody 3G10, a strong
staining was found, further indicating that heparinase III had
cleaved HS (Figure 2D). Taken together, these data strongly
indicate that regeneration is not taking place within the time
frame of the experiment. Neuraminidase had no influence on
the staining profile. Expression of the core protein agrin, the
major HSPG in the GBM, was unaltered (Figure 2E). These data
indicate that GBM HS but not the core protein of HSPG was
removed by heparinase III treatment.
With Peanut agglutinin lectin, which binds to the galactose-
N-acetylgalactosamine (Gal1–3GalNAc) sequence that is un-
Figure 2. Renal HS expression demonstrated by immunofluorescence staining in rats that were administered injections of PBS,
heparinase III, or neuraminidase. Glomerular staining with the anti-HS antibodies HS4C3 (A), EW3D10 (B), and JM403 (C) was
abolished after heparinase III injection (A through C). Anti-HS stub antibody 3G10 (D), reflecting heparinase III reactivity,
stained only heparinase III–treated kidneys (D). Heparinase III has thus removed renal HS. Expression of the HS proteoglycan
(HSPG) core protein agrin, visualized using antibody MI91 (E), was not affected by either heparinase III (E) or neuraminidase (E)
treatment. Bar  50 m; magnification is identical for each photograph.
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masked after removal of neuraminic acid, a glomerular staining
was revealed in neuraminidase-treated rats, in contrast to PBS-
and heparinase III–treated rats (Figure 3A). These results indi-
cate that neuraminidase had cleaved glomerular neuraminic
acid. However, with Sambucus nigra lectin, which stains pre-
dominantly 2,6-linked neuraminic acid, no aberrant staining
could be detected (data not shown). Expression of podocalyxin
(a podocyte-associated, neuraminic acid–containing protein)
was unaltered after neuraminidase as well as heparinase III
injection (Figure 3B).
Electron Microscopic Studies. Presence of GAG in the glo-
merulus was investigated further by cupromeronic blue stain-
ing, which revealed a dense network of fine filaments in the
GBM. Each filament represents a PG with the GAG chains
collapsed onto the core protein (27). The PG filaments that are
associated with the podocytic site of the GBM appeared larger
and more electron dense in comparison with the PG filaments
at the endothelial site. After heparinase III injection, GAG stain-
ing of the GBM was almost completely negative, both at the
podocytic and endothelial sites (Figure 4). A few short fila-
ments were left, which may be due to the presence of some
other GAG (e.g., chondroitin sulfate). As expected, neuraminic
acid cleavage by neuraminidase did not result in an altered
cupromeronic blue staining of the glomerular capillary wall,
because only GAG are visualized by the described method.
By light microscopy, no alterations in renal morphology of
the rats that were administered injections of heparinase III or
neuraminidase were observed (Figure 5). In addition, electron
microscopy revealed that heparinase III injection did not result
in an aberrant glomerular ultrastructure. A normal capillary
wall was observed, viz a GBM with the fenestrated endothelial
cells at the inner side and the podocyte foot processes, inter-
connected by slit diaphragms, at the outer side. Notably, there
was no effacement of podocyte foot processes (Figure 6).
HS and Neuraminic Acid Are Excreted in the Urine after
Heparinase III and Neuraminidase Injection, Respectively
With the use of agarose gel electrophoresis, HS was found in
the urine directly after the first injection of heparinase III,
indicating that the enzyme was active and had liberated HS
(Figure 7A). Some additional HS was secreted in the urine after
the second injection (t  8 to 12 h). No GAG were found in the
urine of the rats that were administered PBS and at any time
point. In the rats that were administered neuraminidase, levels
of free neuraminic acid detected in the urine clearly were
increased at all time points tested compared with the rats that
were administered PBS and heparinase III (Figure 7B). From
these data, it was concluded that HS and neuraminic acid,
released by heparinase III and neuraminidase, respectively,
were excreted in the urine. No major differences in urinary
volume (PBS 10.7  0.9 ml/24 h [n  4], heparinase III 10.3 
1.1 ml/24 h [n  4], neuraminidase 8.2  1.1 ml/24 h [n  2])
or creatinine clearance (PBS 2.3  0.3 ml/min [n  4], hepari-
nase III 2.4  0.4 ml/min [n  4], neuraminidase 2.8  0.3
ml/min [n  2]) were found.
Cleavage of HS Does Not Result in Proteinuria, whereas
Cleavage of Neuraminic Acid Does
SDS-PAGE of urine samples followed by protein staining
with Coomassie brilliant blue revealed a substantial increase in
urinary albumin in the rats that were administered neuramin-
idase but not in the rats that were administered heparinase III.
The proteinuria likely was of glomerular origin because no low
molecular weight proteins, typical for urine of rats with tubular
dysfunction, were detected in the urine of the rats that were
administered neuraminidase (Figure 8A). Furthermore, we did
not detect elevated values of urinary N-acetyl--d-glucosamini-
dase activity, which are increased in case of tubular dysfunc-
tion (data not shown). With the use of electron microscopy, no
aberrant tubular morphology was observed (Figure 9A). The
Figure 3. Sites of removal of neuraminic acid demonstrated by Peanut agglutinin lectin staining. Glomerular staining was strong
in rats that were administered injections of neuraminidase (A) but negative in rats that were administered injections of PBS and
heparinase III (A, A). Staining of the core protein of podocalyxin was the same in all animals (B, B, B). Bar  50 m;
magnification is identical for each photograph. Arrows indicate glomeruli.
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tubular cells, basement membranes, and labyrinth were not
affected. Also, a normal proximal tubular brush border was
observed (Figure 9B).
To quantify the amount of albumin secreted, we used an
ELISA. No increase in urinary albumin could be detected in the
rats that were administered heparinase III (e.g., 12 to 24 h 1.1 
0.2 versus 1.4 1.1 mg albumin/mg creatinine for rats that were
administered heparinase III and PBS, respectively; Figure 8B).
On the contrary, injection of neuraminidase into rats was found
to cause significant albuminuria (e.g., 12 to 24 h 13.6  0.3 mg
albumin/mg creatinine).
Discussion
This study evaluates the role of HS in glomerular permeabil-
ity using a highly controlled in vivo approach. Removal of GBM
HS after cleavage by heparinase III was checked at three levels:
By immunofluorescence using antibodies to various (sulfated)
HS domains, by electron microscopy using cupromeronic blue
staining according to the critical electrolyte concentration
method, and by analysis of HS in the urine. In addition, a
positive control for proteinuria was included, viz treatment
with neuraminidase, which has been reported to induce pro-
teinuria in mice by removal of neuraminic acid from the glo-
merular filtration barrier (22). Using the in vivo approach, we
indeed found that removal of glomerular neuraminic acid re-
sults in acute albuminuria. Removal of HS from the GBM did
not result in acute proteinuria. These results therefore indicate
that HS in the GBM does not play a major, direct role in the
glomerular filtration of proteins.
Various studies suggest a crucial role for HS in glomerular
permeability. Intravenous injection of rats with the monoclonal
anti-HS antibody JM403 resulted in a dosage-dependent in-
crease in albuminuria, which was maximal within 2 h after
injection and decreased thereafter (17). This antibody defines
an HS epitope that contains one or more N-unsubstituted glu-
Figure 4. Electron microscopic detection of sulfated glycosamino-
glycans (GAG) in the glomerular basement membrane (GBM) of
rats that were administered injections of PBS, heparinase III, or
neuraminidase, using cupromeronic blue in the critical electrolyte
concentration mode. Electron-dense filaments reflected GAG.
Note the almost complete lack of GAG in the GBM after hepari-
nase III treatment but not after neuraminidase treatment. Bar 
250 nm; magnification is identical for each photograph.
Figure 5. Delafield’s hematoxylin-eosin staining of kidneys of
rats that were administered injections of PBS, heparinase III, or
neuraminidase. No alterations in renal morphology of the rats
that were administered injections of enzyme were observed.
Bar  100 m; magnification is identical for each photograph.
Figure 6. Electron micrographs of glomeruli from rats that were
administered injections of PBS or heparinase III. No major
abnormalities in the ultrastructure of the glomerular capillary
wall were observed in the rats that were administered injec-
tions of heparinase III. Bar  500 nm; magnification is identical
for each photograph.
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cosamine and d-glucuronic acid residues. l-Iduronic acid and
O-sulfate residues seem to inhibit JM403 binding to HS (26).
Therefore, the albuminuria observed may not be due to block-
ade of the negatively charged sulfate groups of HS, which have
been reported to be responsible for glomerular permselectivity.
Other studies have shown that kidney perfusion with hepa-
rinase III resulted in proteinuria. In their seminal studies, Kan-
war et al. (18,19) reported that treatment of isolated rat kidneys
with heparinase III resulted in an increase of native ferritin (440
kD) in all layers of the GBM and even in the urinary space.
Treatment with heparinase III also resulted in an increased
permeability of the GBM to BSA (68 kD) (19,20). However, from
the study of Jeansson et al. (21), it is unclear whether HS plays
a role in glomerular filtration. In the studies mentioned, there
was no thorough check for whether HS was removed com-
pletely after heparinase III treatment, and (generally) isolated
kidneys were used. In our study, we used intravenous injection
of heparinase III, which may represent a more physiologic
approach to study the role of HS in charge-selective permeabil-
ity.
It still is not clear whether a decrease in GBM HS that is seen
in patients with renal disease is a cause of or a result from
proteinuria. Our study indicates that removal of HS from the
GBM does not result in albuminuria. A number of proteinuric
renal diseases have been reported without aberrant GBM HS
expression, including IgA nephropathy (14), congenital ne-
phrotic syndrome of the Finnish type (31,32), and puromycin
aminonucleoside nephrosis (19).
There already are some additional indications that HS does
not play a major role in the charge-selective barrier properties
of the GBM. In podocyte-specific agrin knockout mice, no pro-
teinuria was observed (33), which also was the case for mice
Figure 7. Urinary excretion of HS, demonstrated by agarose gel electrophoresis (A; urine from individual rats), and of neuraminic
acid, demonstrated by an enzymatic method (B), in rats that were administered injections of PBS, heparinase III, or neuraminidase.
Data are means  SEM (n  4 for PBS and heparinase III; n  2 for neuraminidase). Immediately after heparinase III injection,
HS appeared in the urine. Neuraminidase treatment resulted in an increased urinary excretion of free neuraminic acid. The GAG
standard contains 20 ng of chondroitin sulfate (CS), 20 ng of dermatan sulfate (DS), and 40 ng of HS. *No urine available after 2 h.
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that lack exon 3 of perlecan (which codes for the HS-bearing
domain), although this HSPG is not the major GBM HSPG (34).
However, Morita et al. (35) reported that Hspg2	3/	3 mice show
higher levels of proteinuria than do wild-type mice after intra-
peritoneal injection of BSA. GBM HS, however, did not seem to
be affected, and the degenerative changes that were observed in
podocytes (e.g., fusion of foot processes) and endothelial cells
may have contributed to the proteinuria. Note that in our study
we did not challenge rats with an overload of protein.
Transgenic mice that overexpress human heparanase (endo-
-d-glucuronidase that catalyzes the hydrolytic cleavage of HS)
were reported to have only a slightly elevated level of protein
in the urine (36). Nevertheless, Levidiotis et al. (37) found that
heparanase contributes to the pathogenesis of proteinuria in
passive Heymann nephritis. The effect on HS in the GBM,
however, was not analyzed, and the mechanism through which
heparanase contributed to proteinuria remains to be estab-
lished.
Conclusion
Removal of HS from the GBM using a highly controlled in
vivo rat model does not result in acute proteinuria, indicating
that HS is not a major determinant for the charge-selective
characteristics of the glomerular capillary wall.
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